Join
Live feed
·
PRReleasevia Quantisnow
Madrigal Pharmaceuticals Inc. logo

Madrigal Pharmaceuticals To Announce Topline Results from the Phase 3 MAESTRO-NAFLD-1 Study of Resmetirom on Monday, January 31st

ByQuantisnow·Wall Street's wire, on your screen.
MDGL· Madrigal Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MDGL (Madrigal Pharmaceuticals Inc.) and more on Quantisnow.